The White House released an analysis of the Administration’s Most-Favored-Nation (MFN) drug pricing policy, prepared by administration officials for the Council of Economic Advisers. The report provides the first comprehensive, economy-wide estimate of the policy’s fiscal impact, projecting that aligning U.S. drug prices with those in other high-income countries could generate approximately $529 billion in savings over 10 years. The… (Colocho, May 5, 2026) #Costs, #Drug Pricing, #Prescription Drugs, #Transparency